Biodesix Q1 Revenue Surges 42% to $25.6M, Loss Narrows 30%
BDSX has more than doubled off its 52-week low of $3.436.
Summary
Biodesix Inc reported robust first-quarter 2026 results, with revenue surging 42% year-over-year to $25.6 million and net loss significantly narrowing by approximately 30% to $7.8 million, improving diluted EPS to $(0.81). This strong performance builds on the positive financial trajectory established in FY2025, which saw solid revenue growth and improved profitability. The substantial revenue increase was broad-based, driven by a 37% rise in diagnostic testing and a near doubling of development services, alongside expanding gross margins to 82-84%. This material improvement in both top-line growth and profitability is a significant positive for the company and its investors, indicating strong operational execution and increasing market penetration. Traders will be watching for sustained growth in test volumes and continued progress in biopharma collaborations.
At the time of this announcement, BDSX was trading at $12.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $113.9M. The 52-week trading range was $3.44 to $20.21. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.